CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Adalimumab (ADA) and Infliximab (IFX) therapy during pregnancy in IBD: a prospective assessment of outcome, safety and cord blood levels
DOI 10.1055/s-0033-1347443
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Traussnigg, A Eser, C Primas, P Papay, C Gratzer, S Angelberger, A Mikultis, W Reinisch, M Trauner, H Vogelsang, G Novacek, C Dejaco
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe05/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Disease activity is a major risk factor for gestational complications in IBD. Data on anti-TNFα therapy are still scare. Cord blood levels have been assessed in newborns with IFX, suggesting discontinuation of treatment prior to the third trimester avoiding neonatal exposure. Few data are published on ADA cord blood levels, guiding adequate cessation prior to birth. Aims & Methods: We aimed to evaluate…
Zitieren
Zitierempfehlung
S Traussnigg, A Eser, C Primas, P Papay, C Gratzer, S Angelberger, A Mikultis, W Reinisch, M Trauner, H Vogelsang, G Novacek, C Dejaco (2013) Adalimumab (ADA) and Infliximab (IFX) therapy during pregnancy in IBD: a prospective assessment of outcome, safety and cord blood levels. Zeitschrift für Gastroenterologie (05). https://doi.org/10.1055/s-0033-1347443
Mit CareLit weiterarbeiten